Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 4, 2012, Pages 1098-1103

  Onuchic, Laura ^a   Ferraz de Souza, Bruno ^a   Mendonca, Berenice B ^a   Correa, Pedro Henrique S ^a   Martin, Regina M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; FIBROBLAST GROWTH FACTOR 23; HYDROCHLOROTHIAZIDE; OSTEOCALCIN; PROCOLLAGEN C PROTEINASE;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE PAIN; BRACHYCEPHALY; CASE REPORT; CHILD; CHONDRODYSPLASIA; CODON; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENCY; EXTRACORPOREAL LITHOTRIPSY; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERTELORISM; JANSEN METAPHYSEAL CHONDRODYSPLASIA; LONG TERM CARE; MACROCEPHALY; MUSCLE HYPOTONIA; NEPHROLITHIASIS; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PTH1R GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; SHORT STATURE; SKULL MALFORMATION; WALKING DIFFICULTY;

ADULT; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERCALCEMIA; HYPERCALCIURIA; OSTEOCHONDRODYSPLASIAS; SEVERITY OF ILLNESS INDEX; SODIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME;

EID: 84859531950     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-3082     Document Type: Article

References (26)

1. Schipani E, Kruse K, Jüppner H 1995 A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268:98-100
2. Schipani E, Langman CB, Parfitt AM, Jensen GS, Kikuchi S, Kooh SW, Cole WG, Jüppner H 1996 Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia.NEngl J Med 335:708-714 (Pubitemid 26287357)
3. Schipani E, Langman C, Hunzelman J, Le Merrer M, Loke KY, Dillon MJ, Silve C, Jüppner H 1999 A novel parathyroid hormone (PTH)/PTH-related peptide receptor mutation in Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab 84:3052-3057 (Pubitemid 30646922)
4. Hori M, Shimizu Y, Fukumoto S 2011 Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. Endocrinology 152:4-10
5. Brown WW, Jüppner H, Langman CB, Price H, Farrow EG, White KE, McCormick KL 2009 Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab 94:17-20
6. López I, Rodríguez-Ortiz ME, Almadén Y, Guerrero F, de Oca AM, Pineda C, Shalhoub V, Rodríguez M, Aguilera-Tejero E 2011 Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 80:475-482
7. Rhee Y, Bivi N, Farrow E, Lezcano V, Plotkin LI, White KE, Bellido T 2011 Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49:636-643
8. Jorde R, Sundsfjord J, Fitzgerald P, Bønaa KH 1999 Serum calcium and cardiovascular risk factors and diseases: the Tromso study. Hypertension 34:484-490 (Pubitemid 29426768)
9. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR 2010 Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691
10. Bilezikian JP, Silverberg SJ 2004 Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 350:1746-1751 (Pubitemid 38501143)
11. Parfitt AM, Schipani E, Rao DS, Kupin W, Han ZH, Jüppner H 1996 Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism. J Clin Endocrinol Metab 81:3584-3588 (Pubitemid 26339919)
12. Minagawa M, Arakawa K, Takeuchi S, Minamitani K, Yasuda T, Niimi H 1997 Jansen-type metaphyseal chondrodysplasia: analysis of PTH/PTH-related protein receptor messenger RNA by the reverse transcriptase-polymerase chain method. Endocr J 44:493-499 (Pubitemid 27406756)
13. Schipani E, Jensen GS, Pincus J, Nissenson RA, Gardella TJ, Jüppner H 1997 Constitutive activation of the cyclic adenosine 3&prime,5′- monophosphate signaling pathway by parathyroid hormone (PTH)/PTHrelated peptide receptors mutated at the two loci for Jansen's metaphyseal chondrodysplasia. Mol Endocrinol 11:851-858 (Pubitemid 27241778)
14. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE 2011 Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 108:E1146-E1155
15. Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ 2011 Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96:3541-3549
16. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D 2009 Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 150:4835-4845
17. Kitaoka T, Namba N, Miura K, Kubota T, Ohata Y, Fujiwara M, Hirai H, Yamamoto T, Ozono K 2011 Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta. J Bone Miner Metab 29:598-605
18. Kobayashi K, Imanishi Y, Miyauchi A, Onoda N, Kawata T, Tahara H, Goto H, Miki T, Ishimura E, Sugimoto T, Ishikawa T, Inaba M, Nishizawa Y 2006 Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 154:93-99 (Pubitemid 43250742)
19. Yamashita H, Yamazaki Y, Hasegawa H, Yamashita T, Fukumoto S, Shigematsu T, Kazama JJ, Fukagawa M, Noguchi S 2005 Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation. J Clin Endocrinol Metab 90:4211-4215 (Pubitemid 41058199)
20. Lind L, Skarfors E, Berglund L, Lithell H, Ljunghall S 1997 Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. J Clin Epidemiol 50:967-973 (Pubitemid 27423528)
21. Palmer M, Adami HO, Bergstrom R, Jakobsson S, Akerstrom G, Ljunghall S 1987 Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow-up. Lancet 1:59-62
22. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A 2002 Clinical presentation of primary hyperparathyroidism in Europe-nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 17(Suppl 2):N68-N74 (Pubitemid 35222315)
23. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB 2000 Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.NEngl J Med 342:1478-1483 (Pubitemid 30318271)
24. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G 2005 Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112:2627-2633 (Pubitemid 41532599)
25. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino Sr RB, Gaziano JM, Vasan RS 2007 Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167:879-885 (Pubitemid 46762749)
26. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF 2011 Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305:1119-1127